ImmuPharma (LON:IMM) Shares Up 15% - Here's Why

Key Points

• ImmuPharma's shares surged 15% to a high of GBX 13.85 ($0.19) as trading volume increased by 53%, significantly exceeding the average session volume.
• The company reported a negative EPS of GBX (0.38) in its latest earnings, with analysts predicting a further decline to -339.0000022 EPS for the current fiscal year.
• ImmuPharma specializes in peptide-based therapeutics, with its lead program targeting Lupus through a first-in-class immunomodulator called P140 (Lupuzor™).

ImmuPharma plc (LON:IMM - Get Free Report)'s share price shot up 15% during trading on Wednesday . The company traded as high as GBX 13.85 ($0.19) and last traded at GBX 13 ($0.18). 13,221,054 shares were traded during mid-day trading, an increase of 53% from the average session volume of 8,639,387 shares. The stock had previously closed at GBX 11.30 ($0.15).

ImmuPharma Stock Performance

The stock has a fifty day moving average of GBX 5.71 and a 200 day moving average of GBX 3.70. The company has a market capitalization of £65.79 million, a P/E ratio of -1,479.21 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Research analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.